As viral vector demand surges, fledgling CDMO Matica establishes a beachhead in Texas
Mar 8, 2021 10:23am There's a ready market for viral vectors. Matica, a new CDMO and a subsidiary of South Korea-based CHA Biotech, will soon be poised to help meet the demand. (Harvard University) A lack of global capacity to produce cell and gene therapies has been exacerbated by an even more pressing need: to develop and manufacture coronavirus vaccines. So it appears the timing is right for Matica Biotechnology, a developer and producer of viral vectors, to put down roots in the United States. The brand-new CDMO has teamed up with Texas A&M University and its advanced manufacturing center...
Source: fiercepharma.com